Management of infantile subglottic hemangioma: acebutolol or propranolol?

Int J Pediatr Otorhinolaryngol. 2010 Aug;74(8):959-61. doi: 10.1016/j.ijporl.2010.05.013. Epub 2010 Jun 16.


The successful management of subglottic hemangioma with propranolol has been reported. We report three cases of subglottic hemangioma treated with the cardioselective beta-blocker acebutolol, 8 mg/kg/day. Treatment was efficient in two cases while an open procedure was necessary in the third child. In our experience, acebutolol could be easily administered in oral form twice-a-day only with a dose that was adaptable according to the growth of the child and showed no side effects. We also report a case of rebound growth after beta-mimetic drug use and the efficiency of propranolol treatment in such a recurrence. Considering the lack of side effects and the advantages in terms of administration, we suggest acebutolol as a first-line treatment of subglottic hemangiomas for which intervention is required.

Publication types

  • Comparative Study

MeSH terms

  • Acebutolol / administration & dosage*
  • Adrenergic beta-Antagonists / administration & dosage
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Glottis / pathology
  • Hemangioma / congenital
  • Hemangioma / drug therapy*
  • Humans
  • Laryngeal Neoplasms / congenital
  • Laryngeal Neoplasms / drug therapy*
  • Laryngeal Neoplasms / surgery
  • Laryngoscopy / methods
  • Laryngostenosis / diagnosis
  • Laryngostenosis / etiology
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Recurrence, Local / surgery*
  • Propranolol / administration & dosage*
  • Sampling Studies
  • Treatment Outcome


  • Adrenergic beta-Antagonists
  • Acebutolol
  • Propranolol